<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02015520</url>
  </required_header>
  <id_info>
    <org_study_id>IM133-066</org_study_id>
    <secondary_id>2013-003780-65</secondary_id>
    <nct_id>NCT02015520</nct_id>
  </id_info>
  <brief_title>Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis</brief_title>
  <official_title>A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to identify an appropriate dose of study medication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Disease Activity Score in 28 Joints - C-reactive Protein (DAS28-CRP) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>DAS28-CRP describes severity of rheumatoid arthritis. The components of the joint count assessment are shoulder, elbow, wrist, metacarpophalangeal joints 1 through 5, proximal interphalangeal joints 1 through 5, and the knee joints on the right and left sides, whereby the number of affected joints, tender and swollen, respectively, are counted. The formula used to calculate the score is: DAS28-CRP=0.56 \times \sqrt{TEN28} + 0.28 \times \sqrt{SW28} + 0.36 \times \ln(CRP+1) + 0.014 \times SA+0.96 with:&#xD;
TEN28: number of joints with tenderness upon touching SW28: number of swollen joints CRP: C-reactive Protein SA: subjective assessment of disease activity by the patient during the preceding 7 days on a scale between 0 and 100 (&quot;0&quot;:no activity, &quot;100&quot;: highest activity possible).&#xD;
DAS-CRP score range is 0.49 to 9.07 A DAS-CRP value &gt;5.1 corresponds to a high disease activity A DAS-28 reduction by 0.6 represents a moderate improvement. A reduction &gt;1.2 represents a major improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR) 20/50/70 Response Rates</measure>
    <time_frame>At week 12</time_frame>
    <description>The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Disease Activity Index (CDAI) Score at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76.&#xD;
CDAI &lt;= 2.8 = Remission CDAI &gt; 2.8 and &lt;= 10 = Low Disease Activity CDAI &gt; 10 and &lt;= 22 = Moderate Disease Activity CDAI &gt; 22 = High Disease Activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86.&#xD;
0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Boolean Remission at Week 12</measure>
    <time_frame>At week 12</time_frame>
    <description>Boolean-based definition:&#xD;
At any time point, a patient must satisfy all of the following:&#xD;
TJC ≤1 (0-28) SJC ≤1 (0-28) CRP ≤1 mg/dl Patient Global Assessment ≤1 (on a 0-10 scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Patients report the amount of difficulty they have in performing 8 categories. Each category is scored on a scale ranging from 0 (performed without any difficulty) to 3 (cannot be done at all). The HAQ-DI is then calculated by summing the scores and dividing by the number of categories answered. Total score is between 0-3.0. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment. The HAQ-DI cannot be calculated if the subject does not have scores for at least 6 categories. A response was defined as a subject with a reduction from baseline in HAQ-DI of at least 0.22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With a DAS28-Erythrocyte Sedimentation Rate (ESR) &lt;2.6</measure>
    <time_frame>At week 12</time_frame>
    <description>DAS28- ESR = Disease Activity Scores 28 based on erythrocyte sedimentation rate. A DAS28-ESR below 2.6 is interpreted as remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With a DAS28-C Reactive Protein (CRP) &lt;2.6</measure>
    <time_frame>At week 12</time_frame>
    <description>DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Arm 1: Clazakizumab (Dose # A) (Double-Blind)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clazakizumab Dose # A injection by subcutaneous for 12 weeks + background Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Clazakizumab (Dose # B) (Double-Blind)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clazakizumab Dose # B injection by subcutaneous for 12 weeks + background Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Clazakizumab (Dose # C) (Double-Blind)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clazakizumab Dose # C injection by subcutaneous for 12 weeks + background Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Placebo matching with Clazakizumab (Double-Blind)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clazakizumab Dose # D injection by subcutaneous for 12 weeks + background Methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clazakizumab</intervention_name>
    <arm_group_label>Arm 1: Clazakizumab (Dose # A) (Double-Blind)</arm_group_label>
    <arm_group_label>Arm 2: Clazakizumab (Dose # B) (Double-Blind)</arm_group_label>
    <arm_group_label>Arm 3: Clazakizumab (Dose # C) (Double-Blind)</arm_group_label>
    <other_name>BMS-945429</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Matching with Clazakizumab)</intervention_name>
    <arm_group_label>Arm 4: Placebo matching with Clazakizumab (Double-Blind)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit&#xD;
        www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of active Rheumatoid Arthritis (RA) by standard criteria (American&#xD;
             Rheumatism association (ARA) [1987] or American College of Rheumatology/European&#xD;
             League Against Rheumatism (ACR/EULAR) [2010]) at least 16 weeks prior to screening&#xD;
&#xD;
          -  ACR global functional status class of 1 to 3&#xD;
&#xD;
          -  Documented evidence of inadequate response tumor necrosis factor (TNF) inhibitors&#xD;
&#xD;
          -  All subjects must have been receiving treatment with a minimum dose of 15 mg per week&#xD;
             of Methotrexate for at least 12 weeks and at a stable dose for 28 days prior to&#xD;
             screening. A dose as low as 10 mg Methotrexate is permitted if 15 mg could not be&#xD;
             reached, due to toxicity. In Japan, Korea and Taiwan, a minimum dose of 7.5 mg per&#xD;
             week is permitted. Additional treatment with Hydroxychloroquine or Chloroquine is&#xD;
             permitted, if it is at a dose approved for the treatment of RA and the dose has been&#xD;
             stable for at least 28 days prior to screening&#xD;
&#xD;
          -  Minimum of 6 swollen and 6 tender joints on a 66/68 joint count at screening and at&#xD;
             baseline (Day 1)&#xD;
&#xD;
          -  Elevated High-sensitivity (hs) CRP and/or ESR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active serious infection&#xD;
&#xD;
          -  History of or active tuberculosis (TB)&#xD;
&#xD;
          -  Elevated liver function tests (LFTs)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Associates Of North Alabama, P.C.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic Hot Springs Communities</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valerius Med Group &amp; Res Ctr Of Greater Long Beach, Inc.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Arthritis Research Center</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul Rheumatology, P.A.</name>
      <address>
        <city>Eagan</city>
        <state>Minnesota</state>
        <zip>55121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Research Collaboration, Llc</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Center For Rheumatology</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint And Muscle Medical Care And Research Institute (Jmmcri)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians East, Pa</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Rheumatic Disease Study Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research &amp; Consulting, Llc</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Rheumatology Center Of Oklahoma Pllc</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research Of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Consultants</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Low Country Rheumatology</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Consultants Pllc</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Inflammatory Disease</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Rheumatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>1878</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1121</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cividino Medicine Professional Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 2B6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Rheumatology</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Latha Naik Medical Professional Corporation</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <zip>2608712</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <zip>8078555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kato-shi</city>
        <state>Hyogo</state>
        <zip>6731462</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nagano-shi</city>
        <state>Nagano</state>
        <zip>3808582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sasebo-shi</city>
        <state>Nagasaki</state>
        <zip>8571195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shinjuku-Ku</city>
        <state>Tokyo</state>
        <zip>1608582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>1708476</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nishimura</city>
        <state>Wakayama</state>
        <zip>6492211</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tijuana</city>
        <state>Baja California</state>
        <zip>22010</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cape Town</city>
        <state>Western CAPE</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stellenbosch</city>
        <state>Western Cape</state>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 6, 2013</study_first_submitted>
  <study_first_submitted_qc>December 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2013</study_first_posted>
  <results_first_submitted>March 22, 2021</results_first_submitted>
  <results_first_submitted_qc>March 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2021</results_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo + Methotrexate (MTX)</title>
          <description>Placebo (5% dextrose) subcutaneous (SC) administration once every 4 weeks for 12 weeks plus background methotrexate (MTX)</description>
        </group>
        <group group_id="P2">
          <title>Clazakizumab (1 mg) + MTX</title>
          <description>Clazakizumab (1 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
        </group>
        <group group_id="P3">
          <title>Clazakizumab (5 mg) + MTX</title>
          <description>Clazakizumab (5 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
        </group>
        <group group_id="P4">
          <title>Clazakizumab (25 mg) + MTX</title>
          <description>Clazakizumab (25 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Request to Discontinue Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject no Longer Meets Study Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo + Methotrexate (MTX)</title>
          <description>Placebo (5% dextrose) subcutaneous (SC) administration once every 4 weeks for 12 weeks plus background methotrexate (MTX)</description>
        </group>
        <group group_id="B2">
          <title>Clazakizumab (1 mg) + MTX</title>
          <description>Clazakizumab (1 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
        </group>
        <group group_id="B3">
          <title>Clazakizumab (5 mg) + MTX</title>
          <description>Clazakizumab (5 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
        </group>
        <group group_id="B4">
          <title>Clazakizumab (25 mg) + MTX</title>
          <description>Clazakizumab (25 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="143"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.4" spread="11.21"/>
                    <measurement group_id="B2" value="55.8" spread="11.20"/>
                    <measurement group_id="B3" value="53.4" spread="13.75"/>
                    <measurement group_id="B4" value="52.6" spread="13.21"/>
                    <measurement group_id="B5" value="53.8" spread="12.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Disease Activity Score in 28 Joints - C-reactive Protein (DAS28-CRP) at Week 12</title>
        <description>DAS28-CRP describes severity of rheumatoid arthritis. The components of the joint count assessment are shoulder, elbow, wrist, metacarpophalangeal joints 1 through 5, proximal interphalangeal joints 1 through 5, and the knee joints on the right and left sides, whereby the number of affected joints, tender and swollen, respectively, are counted. The formula used to calculate the score is: DAS28-CRP=0.56 \times \sqrt{TEN28} + 0.28 \times \sqrt{SW28} + 0.36 \times \ln(CRP+1) + 0.014 \times SA+0.96 with:&#xD;
TEN28: number of joints with tenderness upon touching SW28: number of swollen joints CRP: C-reactive Protein SA: subjective assessment of disease activity by the patient during the preceding 7 days on a scale between 0 and 100 (&quot;0&quot;:no activity, &quot;100&quot;: highest activity possible).&#xD;
DAS-CRP score range is 0.49 to 9.07 A DAS-CRP value &gt;5.1 corresponds to a high disease activity A DAS-28 reduction by 0.6 represents a moderate improvement. A reduction &gt;1.2 represents a major improvement</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Modified Intent-to-Treat (mITT) Analysis Population: All randomized subjects who received at least 1 dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Methotrexate (MTX)</title>
            <description>Placebo (5% dextrose) subcutaneous (SC) administration once every 4 weeks for 12 weeks plus background methotrexate (MTX)</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (1 mg) + MTX</title>
            <description>Clazakizumab (1 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (5 mg) + MTX</title>
            <description>Clazakizumab (5 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (25 mg) + MTX</title>
            <description>Clazakizumab (25 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score in 28 Joints - C-reactive Protein (DAS28-CRP) at Week 12</title>
          <description>DAS28-CRP describes severity of rheumatoid arthritis. The components of the joint count assessment are shoulder, elbow, wrist, metacarpophalangeal joints 1 through 5, proximal interphalangeal joints 1 through 5, and the knee joints on the right and left sides, whereby the number of affected joints, tender and swollen, respectively, are counted. The formula used to calculate the score is: DAS28-CRP=0.56 \times \sqrt{TEN28} + 0.28 \times \sqrt{SW28} + 0.36 \times \ln(CRP+1) + 0.014 \times SA+0.96 with:&#xD;
TEN28: number of joints with tenderness upon touching SW28: number of swollen joints CRP: C-reactive Protein SA: subjective assessment of disease activity by the patient during the preceding 7 days on a scale between 0 and 100 (&quot;0&quot;:no activity, &quot;100&quot;: highest activity possible).&#xD;
DAS-CRP score range is 0.49 to 9.07 A DAS-CRP value &gt;5.1 corresponds to a high disease activity A DAS-28 reduction by 0.6 represents a moderate improvement. A reduction &gt;1.2 represents a major improvement</description>
          <population>Modified Intent-to-Treat (mITT) Analysis Population: All randomized subjects who received at least 1 dose of the study medication.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.22"/>
                    <measurement group_id="O2" value="-1.10" spread="0.33"/>
                    <measurement group_id="O3" value="-2.10" spread="0.22"/>
                    <measurement group_id="O4" value="-2.43" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology (ACR) 20/50/70 Response Rates</title>
        <description>The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
        <time_frame>At week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Methotrexate (MTX)</title>
            <description>Placebo (5% dextrose) subcutaneous (SC) administration once every 4 weeks for 12 weeks plus background methotrexate (MTX)</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (1 mg) + MTX</title>
            <description>Clazakizumab (1 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (5 mg) + MTX</title>
            <description>Clazakizumab (5 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (25 mg) + MTX</title>
            <description>Clazakizumab (25 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology (ACR) 20/50/70 Response Rates</title>
          <description>The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
          <population>mITT</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ARC20 responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARC50 responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="21.4"/>
                    <measurement group_id="O4" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARC70 responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="4.8"/>
                    <measurement group_id="O3" value="9.5"/>
                    <measurement group_id="O4" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Disease Activity Index (CDAI) Score at Week 12</title>
        <description>CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76.&#xD;
CDAI &lt;= 2.8 = Remission CDAI &gt; 2.8 and &lt;= 10 = Low Disease Activity CDAI &gt; 10 and &lt;= 22 = Moderate Disease Activity CDAI &gt; 22 = High Disease Activity</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Methotrexate (MTX)</title>
            <description>Placebo (5% dextrose) subcutaneous (SC) administration once every 4 weeks for 12 weeks plus background methotrexate (MTX)</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (1 mg) + MTX</title>
            <description>Clazakizumab (1 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (5 mg) + MTX</title>
            <description>Clazakizumab (5 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (25 mg) + MTX</title>
            <description>Clazakizumab (25 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Disease Activity Index (CDAI) Score at Week 12</title>
          <description>CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76.&#xD;
CDAI &lt;= 2.8 = Remission CDAI &gt; 2.8 and &lt;= 10 = Low Disease Activity CDAI &gt; 10 and &lt;= 22 = Moderate Disease Activity CDAI &gt; 22 = High Disease Activity</description>
          <population>mITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" spread="2.656"/>
                    <measurement group_id="O2" value="-12.8" spread="3.961"/>
                    <measurement group_id="O3" value="-17.4" spread="2.545"/>
                    <measurement group_id="O4" value="-21.6" spread="2.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12</title>
        <description>SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86.&#xD;
0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Methotrexate (MTX)</title>
            <description>Placebo (5% dextrose) subcutaneous (SC) administration once every 4 weeks for 12 weeks plus background methotrexate (MTX)</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (1 mg) + MTX</title>
            <description>Clazakizumab (1 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (5 mg) + MTX</title>
            <description>Clazakizumab (5 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (25 mg) + MTX</title>
            <description>Clazakizumab (25 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12</title>
          <description>SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86.&#xD;
0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity</description>
          <population>mITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.68" spread="2.6846"/>
                    <measurement group_id="O2" value="-13.08" spread="4.0011"/>
                    <measurement group_id="O3" value="-20.15" spread="2.5928"/>
                    <measurement group_id="O4" value="-24.02" spread="2.5677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Boolean Remission at Week 12</title>
        <description>Boolean-based definition:&#xD;
At any time point, a patient must satisfy all of the following:&#xD;
TJC ≤1 (0-28) SJC ≤1 (0-28) CRP ≤1 mg/dl Patient Global Assessment ≤1 (on a 0-10 scale)</description>
        <time_frame>At week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Methotrexate (MTX)</title>
            <description>Placebo (5% dextrose) subcutaneous (SC) administration once every 4 weeks for 12 weeks plus background methotrexate (MTX)</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (1 mg) + MTX</title>
            <description>Clazakizumab (1 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (5 mg) + MTX</title>
            <description>Clazakizumab (5 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (25 mg) + MTX</title>
            <description>Clazakizumab (25 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
        </group_list>
        <measure>
          <title>Boolean Remission at Week 12</title>
          <description>Boolean-based definition:&#xD;
At any time point, a patient must satisfy all of the following:&#xD;
TJC ≤1 (0-28) SJC ≤1 (0-28) CRP ≤1 mg/dl Patient Global Assessment ≤1 (on a 0-10 scale)</description>
          <population>mITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="4.8"/>
                    <measurement group_id="O3" value="2.4"/>
                    <measurement group_id="O4" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 12</title>
        <description>Patients report the amount of difficulty they have in performing 8 categories. Each category is scored on a scale ranging from 0 (performed without any difficulty) to 3 (cannot be done at all). The HAQ-DI is then calculated by summing the scores and dividing by the number of categories answered. Total score is between 0-3.0. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment. The HAQ-DI cannot be calculated if the subject does not have scores for at least 6 categories. A response was defined as a subject with a reduction from baseline in HAQ-DI of at least 0.22.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Methotrexate (MTX)</title>
            <description>Placebo (5% dextrose) subcutaneous (SC) administration once every 4 weeks for 12 weeks plus background methotrexate (MTX)</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (1 mg) + MTX</title>
            <description>Clazakizumab (1 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (5 mg) + MTX</title>
            <description>Clazakizumab (5 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (25 mg) + MTX</title>
            <description>Clazakizumab (25 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 12</title>
          <description>Patients report the amount of difficulty they have in performing 8 categories. Each category is scored on a scale ranging from 0 (performed without any difficulty) to 3 (cannot be done at all). The HAQ-DI is then calculated by summing the scores and dividing by the number of categories answered. Total score is between 0-3.0. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment. The HAQ-DI cannot be calculated if the subject does not have scores for at least 6 categories. A response was defined as a subject with a reduction from baseline in HAQ-DI of at least 0.22.</description>
          <population>mITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.0906"/>
                    <measurement group_id="O2" value="-0.09" spread="0.1307"/>
                    <measurement group_id="O3" value="-0.31" spread="0.0889"/>
                    <measurement group_id="O4" value="-0.46" spread="0.0905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With a DAS28-Erythrocyte Sedimentation Rate (ESR) &lt;2.6</title>
        <description>DAS28- ESR = Disease Activity Scores 28 based on erythrocyte sedimentation rate. A DAS28-ESR below 2.6 is interpreted as remission.</description>
        <time_frame>At week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Methotrexate (MTX)</title>
            <description>Placebo (5% dextrose) subcutaneous (SC) administration once every 4 weeks for 12 weeks plus background methotrexate (MTX)</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (1 mg) + MTX</title>
            <description>Clazakizumab (1 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (5 mg) + MTX</title>
            <description>Clazakizumab (5 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (25 mg) + MTX</title>
            <description>Clazakizumab (25 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With a DAS28-Erythrocyte Sedimentation Rate (ESR) &lt;2.6</title>
          <description>DAS28- ESR = Disease Activity Scores 28 based on erythrocyte sedimentation rate. A DAS28-ESR below 2.6 is interpreted as remission.</description>
          <population>mITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="4.8"/>
                    <measurement group_id="O3" value="7.1"/>
                    <measurement group_id="O4" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With a DAS28-C Reactive Protein (CRP) &lt;2.6</title>
        <description>DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.</description>
        <time_frame>At week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Methotrexate (MTX)</title>
            <description>Placebo (5% dextrose) subcutaneous (SC) administration once every 4 weeks for 12 weeks plus background methotrexate (MTX)</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (1 mg) + MTX</title>
            <description>Clazakizumab (1 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (5 mg) + MTX</title>
            <description>Clazakizumab (5 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (25 mg) + MTX</title>
            <description>Clazakizumab (25 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With a DAS28-C Reactive Protein (CRP) &lt;2.6</title>
          <description>DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.</description>
          <population>mITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="9.5"/>
                    <measurement group_id="O3" value="14.3"/>
                    <measurement group_id="O4" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 weeks for each participant</time_frame>
      <desc>As-Treated Analysis Population: All subjects who received at least 1 dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo + Methotrexate (MTX)</title>
          <description>Placebo (5% dextrose) subcutaneous (SC) administration once every 4 weeks for 12 weeks plus background methotrexate (MTX)</description>
        </group>
        <group group_id="E2">
          <title>Clazakizumab (1 mg) + MTX</title>
          <description>Clazakizumab (1 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
        </group>
        <group group_id="E3">
          <title>Clazakizumab (5 mg) + MTX</title>
          <description>Clazakizumab (5 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
        </group>
        <group group_id="E4">
          <title>Clazakizumab (25 mg) + MTX</title>
          <description>Clazakizumab (25 mg) SC administration once every 4 weeks for 12 weeks + background Methotrexate</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>EOSINOPHILIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>ANAL FISSURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>DENTAL CARIES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>INJECTION SITE RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>AXILLARY PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>DRUG INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>INJECTION SITE BRUISING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>INJECTION SITE VESICLES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>VACCINATION SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC FUNCTION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>LABYRINTHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>SKIN CANDIDA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL MYCOTIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>SKIN ABRASION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>BLOOD CHOLESTEROL INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>BLOOD UREA INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>LOW DENSITY LIPOPROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DYSLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>TEMPOROMANDIBULAR JOINT SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>TENOSYNOVITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>TENSION HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>VULVOVAGINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>THROAT IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>RASH VESICULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>SKIN HYPERPIGMENTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>SECONDARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>CSL Behring</organization>
      <phone>610-878-4000</phone>
      <email>clinicaltrials@cslbehring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

